Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corp's continued advancement of its orphan lung pipeline positions the company for long-term diversification and growth, enhancing its overall value proposition. The company's strategic focus on education and marketing initiatives is expected to boost the uptake of its products, particularly Afrezza and Tyvaso DPI, which have established strong market positions in diabetes and pulmonary arterial hypertension, respectively. Additionally, the promising developments regarding Furoscix and potential approvals for the auto-injector highlight significant future revenue drivers, further supporting a positive outlook for MannKind’s financial performance.

Bears say

MannKind Corp's stock faces a negative outlook primarily due to the announcement of a competitive product by SQ Innovation, which has been linked to a significant decline in share price, highlighting the potential vulnerability of MannKind's market position. Additionally, challenges such as potential lapses in intellectual property protection and adverse regulatory outcomes could further complicate the company’s commercialization efforts and limit its market potential. Finally, the presence of well-capitalized competitors with established products threatens MannKind's ability to maintain pricing power and could lead to further erosion of market share.

MannKind (MNKD) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 6 analysts, MannKind (MNKD) has a Buy consensus rating as of Jan 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.